Details of the Drug

General Information of Drug (ID: DMEMV9D)

Drug Name
Trimeprazine
Synonyms
Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Angioedema 4A00.15 Approved [2]
Urticaria EB00-EB05 Approved [2]
Pruritus EC90 Investigative [2]
Therapeutic Class
Antihistamines
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 298.4
Logarithm of the Partition Coefficient (xlogp) 4.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is well absorbed in the digestive tract []
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C18H22N2S
IUPAC Name
N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine
Canonical SMILES
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C
InChI
InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
InChIKey
ZZHLYYDVIOPZBE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5574
ChEBI ID
CHEBI:9725
CAS Number
84-96-8
DrugBank ID
DB01246
TTD ID
D08HZL
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trimeprazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Trimeprazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [4]
Coadministration of a Drug Treating the Disease Different from Trimeprazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Arn-509. Acute myeloid leukaemia [2A60] [5]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Oliceridine. Acute pain [MG31] [6]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Trimeprazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [4]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Trimeprazine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [4]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Ivabradine. Angina pectoris [BA40] [5]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Trimeprazine and Dronedarone. Angina pectoris [BA40] [7]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Trimeprazine and Amyl nitrite. Angina pectoris [BA40] [8]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Trimeprazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [9]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Posaconazole. Aspergillosis [1F20] [6]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Levalbuterol. Asthma [CA23] [10]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Pirbuterol. Asthma [CA23] [10]
Ephedrine DMMV0KW Moderate Antagonize the effect of Trimeprazine when combined with Ephedrine. Asthma [CA23] [11]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Trimeprazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [11]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Retigabine. Behcet disease [4A62] [6]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Trimeprazine and Cariprazine. Bipolar disorder [6A60] [4]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Eribulin. Breast cancer [2C60-2C6Y] [7]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Lapatinib. Breast cancer [2C60-2C6Y] [6]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Bosutinib. Breast cancer [2C60-2C6Y] [5]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Trimeprazine when combined with Acetylcholine. Cataract [9B10] [12]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [13]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Trimeprazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [14]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [10]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [10]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Trimeprazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [14]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Trimeprazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [14]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [10]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [10]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Trimeprazine and Pasireotide. Cushing syndrome [5A70] [15]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Osilodrostat. Cushing syndrome [5A70] [16]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Trimeprazine and Isocarboxazid. Depression [6A70-6A7Z] [17]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Trimeprazine and Esketamine. Depression [6A70-6A7Z] [18]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Trimeprazine and Mepenzolate. Digestive system disease [DE2Z] [4]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Trimeprazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [19]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Trimeprazine and Deutetrabenazine. Dystonic disorder [8A02] [20]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Ingrezza. Dystonic disorder [8A02] [21]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Trimeprazine and Solifenacin. Functional bladder disorder [GC50] [4]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [7]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [22]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [6]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Trimeprazine and Nebivolol. Hypertension [BA00-BA04] [8]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Trimeprazine and Levamlodipine. Hypertension [BA00-BA04] [8]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Trimeprazine and TAK-491. Hypertension [BA00-BA04] [8]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Trimeprazine and Hydralazine. Hypertension [BA00-BA04] [8]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Trimeprazine and Clevidipine butyrate. Hypertension [BA00-BA04] [8]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Trimeprazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [4]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Trimeprazine and ITI-007. Insomnia [7A00-7A0Z] [4]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [7]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Trimeprazine and Crizotinib. Lung cancer [2C25] [16]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Trimeprazine and Ceritinib. Lung cancer [2C25] [15]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Trimeprazine and Osimertinib. Lung cancer [2C25] [16]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Trimeprazine and Selpercatinib. Lung cancer [2C25] [23]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Trimeprazine and Lumefantrine. Malaria [1F40-1F45] [15]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Trimeprazine and Hydroxychloroquine. Malaria [1F40-1F45] [24]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [5]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Trimeprazine and Vemurafenib. Melanoma [2C30] [7]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and LGX818. Melanoma [2C30] [25]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Trimeprazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [26]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Trimeprazine and Lasmiditan. Migraine [8A80] [18]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Trimeprazine and Flibanserin. Mood disorder [6A60-6E23] [18]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Trimeprazine and Panobinostat. Multiple myeloma [2A83] [27]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Fingolimod. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Trimeprazine and Ozanimod. Multiple sclerosis [8A40] [28]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Romidepsin. Mycosis fungoides [2B01] [6]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Trimeprazine and Nilotinib. Myeloproliferative neoplasm [2A20] [7]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Dasatinib. Myeloproliferative neoplasm [2A20] [15]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Trimeprazine when combined with Dextroamphetamine. Narcolepsy [7A20] [11]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Entrectinib. Non-small cell lung cancer [2C25] [5]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Trimeprazine when combined with Phendimetrazine. Obesity [5B80-5B81] [11]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Trimeprazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [26]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Trimeprazine and Polythiazide. Oedema [MG29] [8]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Lofexidine. Opioid use disorder [6C43] [15]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Rucaparib. Ovarian cancer [2C73] [6]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Trimeprazine when combined with Methamphetamine. Pain [MG30-MG3Z] [11]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Triclabendazole. Parasitic worm infestation [1F90] [6]
Safinamide DM0YWJC Moderate Additive CNS depression effects by the combination of Trimeprazine and Safinamide. Parkinsonism [8A00] [17]
Opicapone DM1BKA6 Moderate Antagonize the effect of Trimeprazine when combined with Opicapone. Parkinsonism [8A00] [29]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Trimeprazine and Rasagiline. Parkinsonism [8A00] [17]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Pimavanserin. Parkinsonism [8A00] [16]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Trimeprazine and Methylscopolamine. Peptic ulcer [DA61] [4]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Trimeprazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [16]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Trimeprazine and Lefamulin. Pneumonia [CA40] [16]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Degarelix. Prostate cancer [2C82] [5]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and ABIRATERONE. Prostate cancer [2C82] [5]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Enzalutamide. Prostate cancer [2C82] [5]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Trimeprazine and Silodosin. Prostate hyperplasia [GA90] [8]
Neupro DMHEAB1 Moderate Antagonize the effect of Trimeprazine when combined with Neupro. Restless legs syndrome [7A80] [29]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Trimeprazine and Iloperidone. Schizophrenia [6A20] [15]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Paliperidone. Schizophrenia [6A20] [6]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Trimeprazine and Molindone. Schizophrenia [6A20] [4]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Trimeprazine and Thiothixene. Schizophrenia [6A20] [4]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Trimeprazine and Amisulpride. Schizophrenia [6A20] [30]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Asenapine. Schizophrenia [6A20] [7]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Trimeprazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [7]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Trimeprazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [15]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [5]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [6]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Trimeprazine and Lenvatinib. Thyroid cancer [2D10] [6]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Trimeprazine and Cabozantinib. Thyroid cancer [2D10] [5]
⏷ Show the Full List of 98 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7237).
2 Trimeprazine FDA Label
3 Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40.
4 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
7 Canadian Pharmacists Association.
8 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
10 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
11 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
12 Multum Information Services, Inc. Expert Review Panel.
13 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
14 Product Information. Anoro Ellipta (umeclidinium-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
17 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
18 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
19 Login IS, Cronin MJ, MacLeod RM "Neuroleptic malignant syndrome caused by dopamine depleting drugs." Neurology 32 (1982): 1022-5. [PMID: 6119652]
20 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
21 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
22 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
23 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
24 Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
25 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
26 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
27 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
28 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
29 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
30 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.